ZLAB vs IMVT โ Head-to-Head Terminal
6-dimension institutional benchmarking across valuation, multi-year operating margins, normalized momentum, and dealer gamma corridors.
Pillar 1 Executive Scorecard & Category Winner Tally
IMVT Captures Institutional Edge (2โ1 Pillars ยท 5โ3 Matrix Metrics)
Tradestie Institutional Equity Comparison Engine assigns the overall head-to-head edge to Immunovant, Inc. Common Stock (IMVT) driven by superior Growth & Margin, Options & Structure while ZLAB counters with relative strength in Momentum & Technical. Fundamentally, ZLAB trades at N/M Forward P/E with -63.0% operating margin (-6.8% YoY revenue) versus IMVT at N/M Forward P/E and 0.0% operating margin (+0.0% YoY). In options structure, ZLAB sits in UNCLASSIFIED (58th %ile IV; Dealer Gamma Walls on Pro) against IMVT sits in CONSOLIDATION (6th %ile IV; Dealer Gamma Walls on Pro).
Pillar 2 Normalized Relative Return Performance (% Indexed to 0%)
Pillar 3 Operating Profitability Benchmark (Trailing 12-Month)
Pillar 4 Head-to-Head Fundamental & Valuation Matrix
| Institutional Metric | ZLAB | IMVT | Criterion | Row Winner |
|---|---|---|---|---|
| Market Capitalization Scale | $3.0B | $7.3B | Larger Scale | IMVT |
| Trailing P/E Ratio Valuation | N/M | N/M | Lower Multiple | Tie |
| Forward P/E Ratio Valuation | N/M | N/M | Lower Multiple | Tie |
| Revenue Growth (YoY) Growth | -6.8% | +0.0% | Higher Growth | IMVT |
| Operating Margin (TTM) Profitability | -63.0% | 0.0% | Higher Margin | IMVT |
| Net Profit Margin Profitability | -44.9% | 0.0% | Higher Margin | IMVT |
| Return on Equity (ROE) Capital Efficiency | -30.0% | -86.5% | Higher ROE | ZLAB |
| 52-Week Range Position Momentum | 60% ($16โ$29) | 49% ($22โ$45) | Stronger Trend | ZLAB |
| Beta / 30D Volatility Risk Regime | 1.19ฮฒ ยท 78% Vol | 1.74ฮฒ ยท 72% Vol | Lower Realized Risk | IMVT |
| Unified Institutional Score Composite Signal | 47.4 / 100 (HOLD) | 39.6 / 100 (SELL) | Higher Composite | ZLAB |